Ablation versus anti-arrhythmic therapy for reducing all hospital episodes from recurrent atrial fibrillation: a prospective, randomized, multi-centre, open label trial.
Prapa KanagaratnamJames McCreadyMuzahir H TayebjeeEwen ShepherdThiagarajah SasikaranDerick ToddNicholas Andrew JohnsonAndreas KyriacouSajad HayatNeil A HobsonIan MannRichard BalasubramaniamZachary I WhinnettMark J EarleySanjiv PetkarRick VeaseySenthil KirubakaranClare CoyleMin-Young KimPhang Boon LimJames O NeillD Wyn DaviesNicholas S PetersDaphne BabalisNicholas W F LintonEmanuela FalaschettiMark A TannerJaymin ShahNeil R PoulterPublished in: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2022)
Clinical Trials Registration: NCT02459574.
Keyphrases
- clinical trial
- open label
- phase ii
- phase iii
- catheter ablation
- atrial fibrillation
- study protocol
- left atrial
- phase ii study
- healthcare
- left atrial appendage
- double blind
- oral anticoagulants
- heart failure
- acute care
- radiofrequency ablation
- randomized controlled trial
- percutaneous coronary intervention
- adverse drug
- squamous cell carcinoma
- emergency department
- placebo controlled
- acute coronary syndrome
- coronary artery disease
- left ventricular
- mitral valve